ScholarIQanswers from OpenAlex & ORCID
Michael Szarek
ResearcherPublications, citations & collaboration network
Michael Szarek is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Michael Szarek have?
ScholarIQindexed works
Michael Szarek has 282 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Michael Szarek have?
ScholarIQcitation count
Michael Szarek has 18,903 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Michael Szarek?
ScholarIQh-index
Michael Szarek has an h-index of 55 in OpenAlex.
What is the i10-index of Michael Szarek?
ScholarIQi10-index
Michael Szarek has an i10-index of 119 in OpenAlex.
What is the ORCID of Michael Szarek?
ScholarIQorcid
The ORCID for Michael Szarek is on the source record.
What is the OpenAlex record for Michael Szarek?
ScholarIQopenalex
The OpenAlex for Michael Szarek is on the source record.
What are the most-cited papers on Michael Szarek?
ScholarIQmost cited works
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Gregory G. Schwartz, Philippe Gabríel Steg, Michael Szarek, Deepak L. Bhatt, Vera Bittner, Rafael Díaz, Jay M. Edelberg, Shaun G. Goodman, Corinne Hanotin, Robert A. Harrington, J. Wouter Jukema, Guillaume Lecorps, Kenneth W. Mahaffey, Angèle Moryusef, Robert Pordy, Kirby Quintero, Matthew T. Roe, William J. Sasiela, Jean‐François Tamby, Pierluigi Tricoci, Harvey D. White, Andreas M. Zeiher
Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure
Deepak L. Bhatt, Michael Szarek, Philippe Gabríel Steg, Christopher P. Cannon, Lawrence A. Leiter, Darren K. McGuire, Julia B. Lewis, Matthew C. Riddle, Adriaan A. Voors, Marco Metra, Lars H. Lund, Michel Komajda, Jeffrey M. Testani, Christopher S. Wilcox, Piotr Ponikowski, Renato D. Lópes, Subodh Verma, Pablo Lapuerta, Bertram Pitt
Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease
Deepak L. Bhatt, Michael Szarek, Bertram Pitt, Christopher P. Cannon, Lawrence A. Leiter, Darren K. McGuire, Julia B. Lewis, Matthew C. Riddle, Silvio E. Inzucchi, Mikhail Kosiborod, David Z.I. Cherney, Jamie P. Dwyer, Benjamin M. Scirica, Clifford J. Bailey, Rafael Díaz, Kausik K. Ray, Jacob A. Udell, Renato D. Lópes, Pablo Lapuerta, Philippe Gabríel Steg
Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial
Gregory G. Schwartz, Laurence Bessac, Lisa G. Berdan, Deepak L. Bhatt, Vera Bittner, Rafael Díaz, Shaun G. Goodman, Corinne Hanotin, Robert A. Harrington, J. Wouter Jukema, Kenneth W. Mahaffey, Angèle Moryusef, Robert Pordy, Matthew T. Roe, Tyrus Rorick, William J. Sasiela, Cheerag Shirodaria, Michael Szarek, Jean‐François Tamby, Pierluigi Tricoci, Harvey D. White, Andreas M. Zeiher, Philippe Gabríel Steg
Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study
Liav Goldstein, Pierre Amarenco, Michael Szarek, Alfred Callahan, Michael G. Hennerici, Henrik Sillesen, Justin A. Zivin, K.M.A. Welch